Viking Therapeutics
Market cap $3.43B 127.5M shares (10-Q, Oct 15, 2026) × $26.88 close Nov 17, 2026
Most recent annual filing: 2026-02-11
- Oral VK2735 corporate update4Q 2026Oral VK2735 corporate update, 4Q 2026, routine
- VANQUISH-1 extension readout2028VANQUISH-1 extension readout, 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
VK2809
VK0214
VK5211
- Hip Fracture
VK0612
- Undisclosed indication
VK3019
Capital (as filed)
- Cash
- $678M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $282M Sep 30, 2026
- Operating cash flow
- −$138M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $960M cash, runway mid-2028 per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure
Offering documents (4)
- 2026-09-25 424B5 · Convertible notes $225M principal · 2% coupon
- 2026-09-25 424B5 · Priced offering 7.86M shares · at $35.00 · $275M gross · 4.8% below the prior close ($36.75, Sep 24, 2026)
- 2026-09-24 FWP · Pricing term sheet 7.86M shares · at $35.00 · $275M gross · 16.0% below the prior close ($41.65, Sep 23, 2026)
- 2026-07-30 S-3ASR · Shelf registration up to $500M aggregate
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-10-29 UPDATE: Viking Therapeutics (VKTX) - The Word Is “Launch” ★ Distilled Pro
- 2026-10-15 UPDATE: Viking Therapeutics (VKTX) - SUNRISE, and a Quiet Correction 🔒 Paid
- 2026-09-24 UPDATE: Viking Therapeutics (VKTX) - The Raise Came Before the Champagne Went Flat 🔒 Paid
- 2026-09-24 UPDATE: Viking Therapeutics (VKTX) - Priced at $35, Not $41 🔒 Paid
- 2026-09-23 UPDATE: Viking Therapeutics (VKTX) - The Killer Update Landed 🔒 Paid
- 2026-07-30 UPDATE: Viking Therapeutics (VKTX) - A $500M Buyback and a New ATM in the Same Filing 🔒 Paid
- 2026-05-01 UPDATE: Viking Therapeutics (VKTX) - Ligand Pulls the Pin on VK2809 🔒 Paid
- 2026-04-30 UPDATE: Viking Therapeutics (VKTX) - The Burn Rate Catches Up 🔒 Paid
- 2026-02-11 Update: Viking Therapeutics (VKTX) – The "Wait and Bleed" Quarter 🔒 Paid
- 2026-01-10 Update: Viking Therapeutics (VKTX) – Commercial Bluff or Go It Alone Suicide Pact? 🔒 Paid
- 2025-12-23 Viking Therapeutics (VKTX): Scientific Due Diligence for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Viking Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-23 Buy core Viking Therapeutics (VKTX): Scientific Due Diligence for Lead and Pipeline Products VK2735 is a credible best-in-class fast follower in obesity with strong M&A appeal; accumulate on dips as the stock is a strategic necessity for pharma giants who missed the GLP-1 wave.
- 2026-01-10 Hold Update: Viking Therapeutics (VKTX) – Commercial Bluff or Go It Alone Suicide Pact? CCO hire is likely a buyout-poker move rather than a go-it-alone commitment; sit tight and watch the JPM presentation before acting on the sell trigger.
- 2026-02-11 Hold Update: Viking Therapeutics (VKTX) – The "Wait and Bleed" Quarter No structural thesis change from Q4 earnings; fortress balance sheet and Q3 2026 catalysts intact, but a 6-month news vacuum warrants patience rather than action.
- 2026-04-30 Hold UPDATE: Viking Therapeutics (VKTX) - The Burn Rate Catches Up Science is tracking but burn jumped 3.6x to ~$103M/quarter, compressing runway to mid-2027 and making a partnership or raise a near-term question rather than a distant one.
- 2026-05-01 Hold UPDATE: Viking Therapeutics (VKTX) - Ligand Pulls the Pin on VK2809 Ligand's purported termination of the TR-Beta license creates litigation overhang on VK2809/VK0214, but VK2735 is wholly owned and the core obesity thesis is untouched.
- 2026-07-30 Buy core UPDATE: Viking Therapeutics (VKTX) - A $500M Buyback and a New ATM in the Same Filing Science intact with maintenance readout weeks away; new ATM and $500M buyback authorization signal management confidence, and the deal package for M&A is stronger than 90 days ago.
- 2026-09-23 Buy core UPDATE: Viking Therapeutics (VKTX) - The Killer Update Landed Maintenance data confirmed 85–90% weight loss retention on monthly dosing with placebo-level GI tolerability, validating the convenience moat and directly answering the core bear case.
- 2026-09-24 Buy core UPDATE: Viking Therapeutics (VKTX) - Priced at $35, Not $41 Raise upsized to $500M but priced at $35 (16% discount), delivering more runway than projected at a higher dilution cost; scientific thesis unchanged and company now funded through pivotal readouts.
- 2026-09-24 Buy core UPDATE: Viking Therapeutics (VKTX) - The Raise Came Before the Champagne Went Flat The $400M raise closes the dilution gap at ~$41 with modest ~4–5% equity dilution, extending runway past VANQUISH readouts and strengthening Viking's negotiating position.
- 2026-10-15 Buy core UPDATE: Viking Therapeutics (VKTX) - SUNRISE, and a Quiet Correction SUNRISE oral Phase 3 started on schedule with lower doses targeting tolerability, but the weekly pill differentiator is gone as the oral formulation is daily like competitors.
- 2026-10-29 Hold UPDATE: Viking Therapeutics (VKTX) - The Word Is "Launch" Burn accelerated to ~$138M/quarter and management's language shifted to standalone launch infrastructure with no mention of partners, moving the go-it-alone sell trigger closer without yet firing it.
- Long call · opened Dec 23, 2025 at $36.41 · -26.2% vs XBI +16.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to initiate Phase 3 oral dosing studies in the fourth quarter of 2026.”
matched to Oral VK2735 · other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (30)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 15, 2026ReleaseViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
- Nov 9, 2026ReleaseViking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
- Oct 29, 202610-QQuarterly report
- Oct 28, 2026ReleaseViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Oct 28, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 confirms $960M cash (better than my post-raise estimate), four Phase 3 trials now running, and language about building "commercial infrastructure" that nudges the go-it-alone sell trigger — but the Fast Follower Factory is executing on every clock it set.BD extracted 2 program updates from this document → VKTX pipeline
- Oct 21, 2026ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
- Oct 14, 2026ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity→ BD updateThe oral VK2735 Phase 3 program (SUNRISE-1 and SUNRISE-2) just launched — the milestone I've been tracking since December — but the stock is down 31% from the September raise price. The science delivered; the market isn't celebrating.BD extracted 1 program update from this document → VKTX pipeline
- Oct 6, 2026ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityBD extracted 1 program update from this document → VKTX pipeline
- Sep 28, 2026ReleaseViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Co
- Sep 28, 20268-KCurrent report: material agreement, debt / obligation
- Sep 25, 2026424B5Prospectus supplement (offering)
- Sep 25, 2026424B5Prospectus supplement (offering)
- Sep 24, 2026ReleaseViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes→ BD updateSummary on the FWP
- Sep 24, 2026FWPFree writing prospectus (offering terms)→ BD updateThe $500M Viking raise just priced: 7.86M shares at $35.00 (a 16% discount to Tuesday's close) plus $225M of 2% convertible notes converting at $50.75. The deal was upsized from $400M — strong institutional demand — but the pricing discount drove VKTX down 11.8% today. Here's what the final terms mean for dilution, runway, and the M&A pitch.
- Sep 23, 2026ReleaseViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes→ BD updateSummary on the 424B5
- Sep 23, 2026424B5Prospectus supplement (offering)→ BD updateThe ink on yesterday's landmark maintenance data was barely dry before Viking announced a concurrent $200M stock + $200M convertible note offering — classic biotech playbook: use a positive catalyst to raise while the window is open, and today's offering reveals exactly how they're bridging the dilution gap I've been flagging since April.
- Sep 23, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 424B5
- Sep 22, 2026ReleaseViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens→ BD updateSummary on the 8-K
- Sep 22, 20268-KCurrent report: other events · EX-99.1→ BD updateToday's VK2735 maintenance data delivered exactly what I've been waiting on since January: monthly dosing holds 85–90% of weight loss, every-other-week dosing holds up to 97%, and GI adverse events during maintenance were indistinguishable from placebo — the convenience moat and the tolerability bear case both resolved in a single readout.BD extracted 1 program update from this document → VKTX pipeline
- Sep 2, 2026ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
- Jul 30, 2026S-3ASRAutomatic shelf registration
- Jul 29, 2026ReleaseViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Jul 29, 20268-KCurrent report: results of operations · EX-99.1
- Jul 29, 202610-QQuarterly report
- May 26, 20268-KCurrent report: shareholder vote
- May 5, 2026ReleaseE-mail Alerts
- Apr 30, 202610-QQuarterly report
- Apr 29, 20268-KCurrent report: results of operations · EX-99.1
- Apr 1, 2026DEFA14AProxy soliciting material
- Apr 1, 2026DEF 14AProxy statement
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Sep 24, 2026305B2305B2→ BD updateSummary on the FWP
- Apr 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 1, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment